Laprosep Komb

Timolol maleate and Latanoprost, the active ingredients in Laprosep Komb, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are indicated for lowering intra‑ocular pressure in glaucoma and ocular hypertension. GNH USA supplies Laprosep Komb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laprosep Komb is used in the management of ocular conditions that require intra‑ocular pressure reduction. - Primary open‑angle glaucoma: lowers pressure to slow optic nerve damage. - Ocular hypertension: reduces elevated pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: assists in controlling pressure when other causes are present.

Common Side Effects: - Eye irritation or burning sensation: mild discomfort after instillation. - Blurred vision: transient visual disturbance. - Redness of the eye: conjunctival hyperemia. - Itching or foreign body sensation: mild ocular pruritus. - Dry eye: reduced tear production. - Increased pigmentation of the iris: gradual darkening.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Acute eye pain: may indicate inflammation. - Vision loss: sudden decrease in visual acuity. - Increased intra‑ocular pressure: paradoxical rise. - Systemic bradycardia or hypotension: due to β‑blockade. - Respiratory distress: especially in asthmatic patients.

Before using Laprosep Komb, consider the following precautions. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: caution as drug may be excreted in milk. - Asthma or COPD: β‑blocker may exacerbate bronchospasm. - Cardiac conduction disorders: avoid in bradycardia or heart block. - Contact lens wear: remove lenses before and wait 15 minutes after dosing. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

When co‑administered with other medicines, monitor for additive effects. Major Interactions (Avoid): - Systemic β‑blockers: may cause excessive bradycardia or hypotension. - Other prostaglandin analog eye drops: increase risk of ocular side effects. - Sympathomimetic ocular agents (e.g., phenylephrine): may reduce IOP‑lowering efficacy. Moderate Interactions (Monitor Closely):\n- Topical corticosteroids: may diminish pressure‑lowering effect. - Anticholinergic eye drops: could affect tear film stability. - Carbonic anhydrase inhibitors: additive IOP reduction may require monitoring.